Levo Gen 2 for Hearing Professionals

Levo Clinical Network

Add a treatment developed specifically for tinnitus to your clinical practice.

Why Levo Gen 2?

Levo Gen 2 combines a sound you personalize for each patient, played every night during sleep, with the Continuous Learning Platform (CLP). The Levo system has been on the U.S. market since 2014 and draws on more than two decades of research.

Tinnitus affects between 10% and 15% of adults (The Lancet, 2013; JAMA Neurology, 2022). What Levo Gen 2 brings to your practice:

    FDA clearance and research

    Levo Gen 2 is FDA-cleared for the temporary relief of tinnitus symptoms in adults (prescription use only). Earlier versions of the Levo system have been studied in peer-reviewed journals.

    Personalized, during sleep

    You characterize each patient’s tinnitus and prescribe a custom sound that plays every night during sleep, at home. The CLP adds tinnitus education, available at any time, step by step.

    Implementation Support

    Training and technical support to integrate Levo Gen 2 into your practice. Clinical care and treatment decisions remain with you.

    What does the platform offer for professionals?

    Levo Gen 2 includes the tools to characterize each patient’s tinnitus, prescribe the treatment and follow its progress over time:

    Levo Gen 2

    Learn more about the therapy and its clinical approach

    Care models

    Levo Gen 2 adapts to each practice and setting. In every model, the referring professional leads the clinical process.

    In person

    The evaluation and the main follow-up visits take place at the referring professional’s clinic.

    Remote (where regulations allow)

    Where clinical conditions and local regulations allow, the referring professional can carry out stages of the treatment through telehealth.

    Hybrid

    Combines in-person care by the referring professional with remote Implementation Support.

    Contact

    Briefly tell us about your case, and a member of our team will get back to you.